Does CVS–Aetna Spell the End of Business as Usual?

The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.

Bibliographische Detailangaben

Veröffentlicht in:	The New England journal of medicine Jg. 378; H. 7; S. 593 - 595
1. Verfasser:	Dafny, Leemore S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 15.02.2018
Schlagworte:	Acquisitions & mergers Antitrust Drug stores Health care policy Market shares Pharmaceutical industry Pharmacy Prescription drugs Primary care
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!